339186-68-4

Basic information

• Product Name: Matuzumab
• Synonyms: Matuzumab;Emd 72000;Emd-72000;Kgaa;Merck kgaa
• CAS NO: 339186-68-4
• Molecular Weight: 0
• Mol File: 339186-68-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Matuzumab(CAS DataBase Reference)
• NIST Chemistry Reference: Matuzumab(339186-68-4)
• EPA Substance Registry System: Matuzumab(339186-68-4)

Safety Data

• Hazardous Substances Data: 339186-68-4(Hazardous Substances Data)

Usage

Description

Matuzumab is a monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), a protein commonly overexpressed in various types of cancer cells. It functions by binding to the EGFR, thereby inhibiting the receptor's ability to signal the cells to grow and divide, which can contribute to the slowing of cancer progression and the improvement of patient outcomes. Matuzumab is currently under investigation in clinical trials for its efficacy in treating different cancer types, with early results indicating promising potential in cancer therapy. It also exhibits a favorable safety profile and tolerability in patients, positioning it as a potentially valuable treatment option in oncology.

Uses

Used in Oncology:
Matuzumab is used as a targeted therapy for the treatment of various types of cancer, including lung and head and neck cancers. It is employed for its ability to bind to the EGFR on cancer cells, preventing the receptor from signaling the cells to grow and divide, which can help slow the progression of cancer.
Used in Clinical Trials:
Matuzumab is being studied in clinical trials to evaluate its efficacy in treating different types of cancers. These trials aim to determine the optimal dosage, administration methods, and potential side effects, as well as to assess its effectiveness in combination with other cancer therapies.
Used in Cancer Therapy Research:
Matuzumab is used as a subject of research to explore its potential in cancer therapy. Studies are being conducted to understand its mechanism of action, its impact on various signaling pathways related to cancer cell growth and division, and its potential synergistic effects when combined with conventional chemotherapeutic drugs.
Used in Patient Care:
Matuzumab is used in patient care for those diagnosed with cancers that overexpress the EGFR. Its good safety profile and tolerability make it a potentially valuable treatment option for improving patient outcomes and managing the progression of the disease.